The University of Dundee is renowned for success in innovation.

We've fostered countless successful partnerships with industry through collaborative research projects, Knowledge Transfer Partnerships, consultancy, service work and more. We have over 20 active spin-out companies that have contributed over 1000 jobs and £230m to the Scottish economy (2016 impact study). In 2016/17, we earned an excess of £5m from licensing and commercialisation activity.

View examples of some of our collaborations and spinouts below, and contact us if you would like to find out more.


CERN and the School of Science & Engineering

CERN logoDevelopments from Prof Amin Abdolvand's research group is having an impact on the future of the Large Hadron Collider (LHC) at CERN. “The LESS method should yield many successful applications in the future; this is just one opportunity that will have a dramatically positive impact for the LHC and its High Luminosity configuration" - Peter McIntosh, Deputy Head of STFC ASTeC (Accelerator Science and Technology Centre).

Rautomead Ltd and the School of Science & Engineering

Rautomead logoRautomead Ltd are specialists in the construction of continuous casting equipment for non-ferrous metals, copper, copper alloys, gold and silver, with expertise in the design, manufacture and sale of continuous casting equipment. In 2012, Rautomead and the University started a Knowledge Transfer Partnership (funded by Technology Strategy Board/Innovate UK) to develop new complex high performance alloys, improving the capability and performance of the company's continuous casting machinery. Our partnership with Rautomead has grown over the years, where the company benefits from our academic expertise and state-of-the-art laboratory equipment, supporting Rautomead's R&D effort.

  • Rautomead Ltd and the Department of Electronics, Engineering and Physics
  • Find out more about Knowledge Transfer Partnerships (KTPs): Industry Funding Opportunities

Rautomead Continuous Casting Equipment

Alere and FIND - a rapid test for sleeping sickness

FIND and Alere - diagnostic test for human African Sleeping SicknessInternational, non-profit organisation FIND and the diagnostics company Alere have launched a second-generation rapid diagnostic test for sleeping sickness. Sleeping sickness, or Human African Trypanosomiasis (HAT), is caused by parasites transmitted by tsetse flies in sub-Saharan Africa and has a devastating impact, causing thousands of deaths each year. The test has been developed from research performed in the laboratories of Professor Mike Ferguson at Dundee and Professor Mark Carrington at Cambridge, with device prototyping done at BBI Solutions in the Dundee Technology Park.

Boehringer Ingelheim - developing PROTACS, a novel class of medicine

‌Boehringer Ingelheim and the University of Dundee have joined forces in an exciting collaboration aiming to develop a novel class of medicines that target disease-causing proteins for degradation. The collaboration brings together the expertise of the University’s Dr Alessio Ciulli, one of the pioneers in the field of PROteolysis TArgeting Chimeric molecules (PROTACs), with Boehringer Ingelheim’s expertise in drug discovery and clinical development of new therapeutic agents.

Division of Signal Transduction Therapy (DSTT)

DSTT is a unique collaboration between academic researchers at the University and the world's leading pharmaceutical companies, working together in the area of signal transduction to accelerate drug discovery.

Drug Discovery Unit - industry collaborations that address unmet medical need

Drug Discovery Unit (DDU) at the University of Dundee‌‌The Drug Discovery Unit (DDU) in the School of Life Sciences has generated £2.7 million income to the University from industrial collaborations for their high quality therapeutic projects where there is a clinical unmet need. The Drug Discovery Unit (DDU) was founded in 2006 with the aim of translating basic science into lead compounds to validate putative drug targets, to use as tools to investigate disease pathways and, when appropriate, advance to pre-clinical drug candidates. ‌The DDU tackles unmet medical need through small molecule drug discovery, bridging the gap between academic scientific research and commercial drug discovery and development.

GALVmed and BBI Solutions - developing a new diagnostic for animal trypanosomiasis

Researchers at the University have teamed up with GALVmed and BBI Solutions to develop an effective and simple diagnostic test for T. vivax, an infection which causes muscle wasting and death in cattle in sub-Saharan Africa and South America. Approximately 60 million cattle are at risk from the associated disease, and the socio-economic impacts are profound. GALVmed are now working with scientists, manufacturers and distributors in the 40 countries where the disease is rife to create a sustainable supply chain for the final product. 

GlaxoSmithKline tackle neglected diseases with the School of Life Sciences

‌Researchers at the University of Dundee are working with GSK in an effort to find new drugs to treat some of the world’s most devastating parasitic diseases - visceral and cutaneous leishmaniasis, and Chagas’ disease. These neglected diseases cause substantial suffering and an estimated 60,000 deaths annually world-wide. Recent funding from Wellcome enable sthe established Dundee/GSK team to continue their work to develop novel drugs to treat these diseases over the next five years.

My Diabetes My Way - a project with NHS Scotland

My Diabetes My Way is the NHS Scotland interactive diabetes website for people with diabetes and their family, friends and carers. The project provides resources including clinical information to help patients, friends, family and carers to better understand and manage their diabetes. The project is led by the University of Dundee, with Dr Debbie Wake and Dr Scott Cunningham from the School of Medicine the Clinical and Technical Leads.

Psoriasis, allergies and Alzheimer's disease - vaccines are a possibility

Research from the Universities of Dundee and Oxford has shown how combining the tetanus vaccine with a viral particle that normally affects cucumbers can be used to treat psoriasis and allergies, and may even protect against Alzheimer's disease.



In4Derm is developing a portfolio of topical drug discovery projects for major unmet needs in dermatology.  For genetically and/or clinically validated targets, where‌systemic drugs are unsuitable, we re-engineer advanced molecules into novel soft drugs. 

Our portfolio contains four projects which are developing topical treatments for acne, psoriasis, atopic dermatitis, allergic dermatitis, keloid scaring and orphan oncology indications.

Our aspiration is to spin out a company based on our work and we are interested in hearing from potential investors, downstream partners or collaborators with an interest in our technology or the assets we are developing.

For any enquiries please contact: Dr Andrew Woodland at


Scottish and Southern Electricity Networks (SSEN) and the School of Social Sciences

Researchers within the School of Social Sciences worked closely with colleagues at SSEN to understand, and then transform, how the company supports 'vulnerable' people within communities. The Knowledge Transfer Partnership (KTP) identified a knowledge gap in the understanding of vulnerability, leading SSEN to provide specialist training to employees in its customer contact centres and depots, helping the organisation provide the most appropriate service for each of its customers.

Derbyshire Fire and Rescue Service and the School of Science and Engineering

Conventional smoke alarms often fail to wake children, and research from the Centre for Anatomy and Human Identification (CAHID) at the University has identified more effective combinations of tones and frequencies to wake both boys and girls. The team have recruited families from across the UK to take part in a large-scale citizen science project, in collaboration with Derbyshire Fire and Rescue Service and other partners.


With a strong culture for innovation at the University, it's no surprise we have a host of successful spinouts formed from University research and expertise.

Three of our spinouts were winners at the Courier Business Awards 2017 - congratulations to:

  • MyWayDigital Health - Enterprise in Education Award, sponsored by Research and Innovation Services
  • STAR-DundeeDesign & Innovation Business of the Year
  • ExscientiaScience & Technology Business of the Year

Find below an introduction to some of our spinouts.

DC Biosciences logo

DC Biosciences, formerly Dundee Cell Products, was founded in 2006 as a spinout of the internationally renowned School of Life Sciences by Professor Angus Lamond (Lamond Lab). DC Biosciences is recognised as a leading global player in proteomics services and molecular biology. Since spin-out, the company has developed close interactions with researchers across a number of internationally acclaimed institution and research organisations.

Exscientia logo

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. Formed in 2012, the company were the first to automate drug design, surpassing conventional approaches. The company's founder and CEO is Prof Andrew Hopkins, Chair of Medicinal Informatics in the School of Life Sciences at the University.

Glencoe Software logo

Glencoe Software provides scientific image data solutions, supporting viewing, sharing, analysis and management of large sets of images and metadata. Glencoe's products are utilised in several world-leading labs, biotechs and pharmaceutical companies. The company was formed in 2005 by Prof Jason Swedlow from the School of Life Sciences as the commercial arm of the Open Microscopy Environment, a community-led, open source data specification and software development consortium.

MyWay Digital Health, spinout company from the University of Dundee

MyWay Digital Health spun out from the University in 2017, and it aims to improve the lives of people living with diabetes through data driven technology solutions. Their flagship product, My Diabetes My Way, is a multi-award winning online self-management platform for people with diabetes, providing resources including clinical information to help patients, friends, family and carers. Dr Debbie Wake and Dr Scott Cunningham from the School of Medicine are the Clinical and Technical Leads. My Diabetes My Way has secured a large number of high profile prizes in 2017, with awards including International eHealth Prize, Enterprise in Education Award at the Courier Business Awards 2017, and an £80k award from Scottish Edge.

STAR-Dundee logo

STAR-Dundee is an aerospace engineering company, focused on spacecraft on-board data-handling and processing technology. The company was formed in 2002 by Prof Steve Parkes, Chair of Spacecraft Electronic Systems in the School of Science and Engineering. The Space Technology Centre at the University led the technical work to develop the SpaceWire standard for data communications onboard satellites and spacecraft, and SpaceWire is now being used on ESA, NASA and JAXA spacecraft as well as by agencies, research organisations and space industry across the world.

Nicola Madill

Marketing Manager

  +44 (0)1382 381893